Healthcare in the Cloud
The latest developments in data and computing are starting to have a transformational effect on the healthcare industry. This infographic deals specifically with cloud computing and accessing patient records, but it is even more than that.
Wearable technology and apps, for instance, will be interfaced with the cloud to allow users to provide and interpret important data in real-time. Blood sugar, heart rates, temperature, and other important diagnostics can be taken and compared against millions of other patients. People living with chronic disease will be able to much better monitor their health, and people focused on preventative measures will have many new ways to interface with their bodies.
This two-way information exchange also allows patients and doctors to communicate better with one another. Patient diagnostics are being sent in real-time to doctors, but the practitioner could “push” notifications back. For example, recommending less sugar intake.
Doctors and medical practitioners will be able to have access to mountains of new data, with insights produced through big data. This will allow for more accurate diagnosis and treatment recommendations. Hospitals and clinics will be able to save money on managing their data, which will decrease costs significantly and allow them to focus efforts in more important places.
New technologies, including healthcare in the cloud, have big potential for investors as well. Venture Capitalists are now putting billions of dollars into such investments each year now, well up from around $343 million in 2010.
Original graphic from: MBA Healthcare Management?
Visualizing Over A Century of Global Fertility
Global fertility has almost halved in the past century. Which countries are most resilient, and which have experienced the most dramatic changes over time?
Visualizing Over A Century of World Fertility
In just 50 years, world fertility rates have been cut in half.
This sea change can be attributed to multiple factors, ranging from medical advances to greater gender equity. But generally speaking, as more women gain an education and enter the workforce, they’re delaying motherhood and often having fewer children in the process.
Today’s interactive data visualization was put together by Bo McCready, the Director of Analytics at KIPP Texas. Using numbers from Our World in Data, it depicts the changes in the world’s fertility rate—the average number of children per woman—spanning from the beginning of the 20th century to present day.
A Demographic Decline
The global fertility rate fell from 5.25 children per woman in 1900, to 2.44 children per woman in 2018. The steepest drop in this shift happened in a single decade, from 1970 to 1980.
In the interactive graphic, you’ll see graphs for 200 different countries and political entities showing their total fertility rate (FTR) over time. Here’s a quick summary of the countries with the highest and lowest FTRs, as of 2017:
|Top 10 Countries||Fertility rate||Bottom 10 Countries||Fertility Rate|
|🇳🇪 Niger||7.13||🇹🇼 Taiwan||1.22|
|🇸🇴 Somalia||6.08||🇲🇩 Moldova||1.23|
|🇨🇩 Democratic Republic of Congo||5.92||🇵🇹 Portugal||1.24|
|🇲🇱 Mali||5.88||🇸🇬 Singapore||1.26|
|🇹🇩 Chad||5.75||🇵🇱 Poland||1.29|
|🇦🇴 Angola||5.55||🇬🇷 Greece||1.3|
|🇧🇮 Burundi||5.53||🇰🇷 South Korea||1.33|
|🇺🇬 Uganda||5.41||🇭🇰 Hong Kong||1.34|
|🇳🇬 Nigeria||5.39||🇨🇾 Cyprus||1.34|
|🇬🇲 Gambia||5.29||🇲🇴 Macao||1.36|
At a glance, the countries with the highest fertility are all located in Africa, while several Asian countries end up in the lowest fertility list.
The notable decade of decline in average global fertility can be partially traced back to the actions of the demographic giants China and India. In the 1970s, China’s controversial “one child only” policy and India’s state-led sterilization campaigns caused sharp declines in births for both countries. Though they hold over a quarter of the world’s population today, the effects of these government decisions are still being felt.
Population Plateau, or Cliff?
The overall decline in fertility rates isn’t expected to end anytime soon, and it’s even expected to fall past 2.1 children per woman, which is known as the “replacement rate”. Any fertility below this rate signals fewer new babies than parents, leading to an eventual population decline.
Experts predict that world fertility will further drop from 2.5 to 1.9 children per woman by 2100. This means that global population growth will slow down or possibly even go negative.
Africa will continue to be the only region with significant growth—consistent with the generous fertility rates of Nigeria, the DRC, and Angola. In fact, the continent is expected to house 13 of the world’s largest megacities, as its population expands from 1.3 billion to 4.3 billion by 2100.
The Big Pharma Takeover of Medical Cannabis
The Big Pharma industry is entering the cannabis space, by swapping patients for patents. But what are the impacts of such a takeover?
The Big Pharma Takeover of Medical Cannabis
As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.
Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.
Who are “Big Pharma”?
The term refers to some of the largest pharmaceutical companies in the world, considered especially influential as a group. To give a sense of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.
So far, Big Pharma has watched the cannabis industry from the sidelines, deterred by regulatory concerns. What we are seeing now is the sleeping giant’s takeover slowly intensifying as more patents, partnerships, and sponsored clinical trials come to fruition.
Could Cannabis be Sold Over the Counter?
The cannabis plant has been used in medicine for 6,000 years. However, there is still considerable debate around the role it plays in healthcare today. There are currently almost 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the cannabis plant’s extract.
Cannabis relies on CBD’s therapeutic properties, and recent studies suggest it may be useful in combating a variety of health conditions, such as:
- Multiple sclerosis
- Cancer side effects
As of 2019, 33 states and the District of Columbia have legalized cannabis for medical use. Its potential for pain management has led some experts to recommend it as an alternative to addictive painkillers, with one study of 13 states showing opiate-related deaths decreasing by over 33% in the six years since medical cannabis was legalized.
As the industry evolves, data is becoming increasingly important in understanding the potential of cannabis—both as a viable medical treatment, and as a recreational product. The shift away from anecdotal evidence towards big data will inform future policies, and give rise to a new era of consumer education.
Big Pharma’s Foray into Cannabis
Further legalization of cannabis will challenge Big Pharma’s bottom line, and poach more than $4 billion from pharma sales annually. In fact, medical cannabis sales are projected to reach $5.9 billion in 2019, from an estimated 24 million patients.
Seven of Canada’s top 10 cannabis patent holders are major multinational pharmaceutical companies, a trend that is not unique to Canada.
|Company Rank||🇨🇦 Canadian Patents||Company Rank||🇺🇸 U.S. Patents|
|1. Novartis||21||1. Abbvie||59|
|2. Pfizer||14||2. Sanofie||39|
|3. GW Pharmaceuticals||13||3. Merck||35|
|4. Ericsson||13||4. Bristol-Myers Squibb||34|
|5. Merck||11||5. GW Pharmaceuticals||28|
|6. Solvay Pharmaceuticals||7||6. Pfizer||25|
|7. Kao Corporation||7||7. Hebrew University of Jerusalem||19|
|8. Ogeda SA||7||8. Roche||17|
|9. Sanofi||6||9. University of Connecticut||16|
|10. University of Connecticut||6||10. U.S. Health and Human Services||13|
It comes as no surprise that many pharmaceutical giants have already formed strong partnerships with cannabis companies, such as Novartis and Tilray, who will develop and distribute medical cannabis together in legal jurisdictions around the world.
Data is the Missing Link
While the body of knowledge about the many uses of cannabis continue to grow, clinical evidence is key for widespread adoption.
Products backed by data will be a defining criteria for major companies to come into the market en masse. And ultimately, Big Pharma’s entry could accelerate public understanding and confidence in cannabis as a viable option for a range of ailments, and mark the next major milestone for the industry.
Markets7 months ago
The Jeff Bezos Empire in One Giant Chart
Maps9 months ago
Mercator Misconceptions: Clever Map Shows the True Size of Countries
Advertising6 months ago
Meet Generation Z: The Newest Member to the Workforce
Misc9 months ago
24 Cognitive Biases That Are Warping Your Perception of Reality
Advertising5 months ago
How the Tech Giants Make Their Billions
Technology8 months ago
The 20 Internet Giants That Rule the Web
Chart of the Week7 months ago
Chart: The World’s Largest 10 Economies in 2030
Environment6 months ago
The World’s 25 Largest Lakes, Side by Side